Remote regulatory assessments: Pharma, device groups want more details on FDA guidance
Regulatory NewsJoanne S. Eglovitch
Audit/inspectionComplianceMedical DevicesNorth AmericaPharmaceuticalsQuality Assurance and ControlRegulatory Intelligence/Policy